Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity

Drug firm Zydus Cadila said it has received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis, in the American market

from Latest News https://ift.tt/387TCjD
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share